Stockscreener 앱 받기
3.19
0.31%
-0.01
시간 외 거래:
3.23
0.04
+1.25%
Mannkind Corp 주식(MNKD)의 최신 뉴스
Price to earnings forward of MannKind Corporation – SWB:NNFN - TradingView
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - Yahoo Finance
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth - TradingView
Chardan starts coverage of MannKind stock with a USD 10.00 target - AD HOC NEWS
MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 - GuruFocus
Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data - Yahoo Finance
MNKD: IPF pipeline advances as ReadyFlow and TYVASO DPI support growth and diversification - TradingView
Chardan initiates MannKind stock coverage with buy rating on pipeline - Investing.com
This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
MNKD Initiates Coverage On Chardan Capital -- Price Target Annou - GuruFocus
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance
MannKind stock rises 4.54 percent on Nasdaq at EUR 2.81 - ad-hoc-news.de
MannKind CEO to join panel on chronic respirato... - Pluang
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan
New data supports Furoscix ReadyFlow autoinject... - Pluang
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus
MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada
Form 144 MannKind Corporation For: 25 September - Investing.com India
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
2.34%
9.38%
자본화:
|
볼륨(24시간):